E. Berger

发表

Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease.

J. Farber, P. Murphy, E. Berger, 1999, Annual review of immunology.

HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor

Paul E. Kennedy, C. Broder, E. Berger, 1996, Science.

Efficient Infection of a Human B Cell Line with Cell-Free Kaposi's Sarcoma-Associated Herpesvirus

S. Moir, Stephen J Dollery, L. Kardava, 2013, Journal of Virology.

A new classification for HIV-1

B. Korber, J. Sodroski, Q. Sattentau, 1998, Nature.

HIV Entry and Tropism

E. Berger, 1998 .

Reconsidering targeted toxins to eliminate HIV infection: you gotta have HAART.

I. Pastan, B. Moss, I Pastan, 1998, Proceedings of the National Academy of Sciences of the United States of America.

HIV gp 120 INTERACTIONS WITH CORECEPTORS : INSIGHTS FROM STUDIES WITH CCR 5-BASED PEPTIDES

E. Berger, G. Alkhatib, 2022 .

Humoral Antibody Responses to HIV Viral Proteins and to CD4 Among HIV Controllers, Rapid and Typical Progressors in an HIV-Positive Patient Cohort

B. Agan, A. Saphire, E. Berger, 2016, AIDS research and human retroviruses.

sCD4-17b bifunctional protein: Extremely broad and potent neutralization of HIV-1 Env pseudotyped viruses from genetically diverse primary isolates

E. Berger, B. Dey, V. Villarroel, 2010, Retrovirology.

Virus Receptor Wars: Entry Molecules Used for and Against Viruses Associated with AIDS

E. Berger, 2008 .

Specific inhibition of HIV-1 coreceptor activity by synthetic peptides corresponding to the predicted extracellular loops of CCR5.

E. Berger, L. Agrawal, G. Alkhatib, 2004, Blood.

Vaccinia‐Based Reporter Gene Cell‐Fusion Assays to Quantitate Functional Interactions of HIV Envelope Glycoprotein with Receptors

E. Berger, B. Dey, 2003, Current protocols in immunology.

And the Best Picture is — the HIV gp120 envelope, please!

E. Berger, 1998, Nature Structural &Molecular Biology.

Fusogenic mechanisms of enveloped-virus glycoproteins analyzed by a novel recombinant vaccinia virus-based assay quantitating cell fusion-dependent reporter gene activation

C. Broder, E. Berger, O. Nussbaum, 1994, Journal of virology.

CC Chemokine Receptor 5-Mediated Signaling and HIV-1 Co-receptor Activity Share Common Structural Determinants

S. Mummidi, D. Light, S. Ahuja, 1997, The Journal of Biological Chemistry.

Human immunodeficiency virus envelope glycoprotein/CD4-mediated fusion of nonprimate cells with human cells

B. Moss, P. Ashorn, E. Berger, 1990, Journal of virology.

Culturing HCV: challenges and progress

E. Berger, B. Saunier, M. Triyatni, 2011 .

Genetic polymorphism in CX3CR1 and risk of HIV disease.

J. Goedert, P. Rosenberg, C. Kleeberger, 2000, Science.

Determinants of HIV-1 Coreceptor Function on CC Chemokine Receptor 3

P. Murphy, E. Berger, G. Alkhatib, 1997, The Journal of Biological Chemistry.

Rapid Transduction and Expansion of Transduced T Cells with Maintenance of Central Memory Populations

E. Rakasz, M. Pampusch, E. Connick, 2019, Molecular therapy. Methods & clinical development.

HIV coreceptors: from discovery and designation to new paradigms and promise.

E. Berger, G. Alkhatib, 2007, European journal of medical research.

Differential regulation of HIV-1 fusion cofactor expression by CD28 costimulation of CD4+ T cells.

B. Levine, C. June, O. Weislow, 1997, Science.

Bispecific chimeric antigen receptors targeting the CD4 binding site and high-mannose Glycans of gp120 optimized for anti-human immunodeficiency virus potency and breadth with minimal immunogenicity.

D. Vargas-Inchaustegui, E. Berger, B. Dey, 2018, Cytotherapy.

A Trispecific Anti-HIV Chimeric Antigen Receptor Containing the CCR5 N-Terminal Region

E. Berger, V. Bundoc, Agnes Hajduczki, 2020, Frontiers in Cellular and Infection Microbiology.

Kaposi's Sarcoma-Associated Herpesvirus Fusion-Entry Receptor: Cystine Transporter xCT

E. Berger, J. Kaleeba, 2006, Science.

Selective killing of Kaposi's sarcoma-associated herpesvirus lytically infected cells with a recombinant immunotoxin targeting the viral gpK8.1A envelope glycoprotein

B. Chandran, E. Berger, Deboeeta Chatterjee, 2012, mAbs.

Evidence for pro-β-nerve growth factor, a biosynthetic precursor to β-nerve growth factor

E. Shooter, E. Berger, 1977 .

A New Model to Produce Infectious Hepatitis C Virus without the Replication Requirement

E. Berger, B. Saunier, M. Triyatni, 2011, PLoS pathogens.

A new SIV co-receptor, STRL33

K. Peden, J. Farber, E. Berger, 1997, Nature.

HIV's response to a CCR5 inhibitor: I'd rather tighten than switch!

J. Farber, E. Berger, 2002, Proceedings of the National Academy of Sciences of the United States of America.

Cell type-specific fusion cofactors determine human immunodeficiency virus type 1 tropism for T-cell lines versus primary macrophages

C. Broder, E. Berger, G. Alkhatib, 1996, Journal of virology.

An anti-HIV microbicide comes alive.

E. Berger, L. Lagenaur, 2005, Proceedings of the National Academy of Sciences of the United States of America.

A soluble recombinant polypeptide comprising the amino-terminal half of the extracellular region of the CD4 molecule contains an active binding site for human immunodeficiency virus.

B. Moss, T. Fuerst, E. Berger, 1988, Proceedings of the National Academy of Sciences of the United States of America.

Recombinant CD4-Pseudomonas exotoxin hybrid protein displays HIV-specific cytotoxicity without affecting MHC class II-dependent functions.

I. Pastan, B. Moss, D. Fitzgerald, 1990, AIDS research and human retroviruses.

Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein

I. Pastan, B. Moss, T. Fuerst, 1988, Nature.

CC chemokine receptors 1 and 3 are differentially regulated by IL-5 during maturation of eosinophilic HL-60 cells.

C. Combadière, E. Berger, H. Tiffany, 1998, Journal of immunology.

Patterns of CCR5, CXCR4, and CCR3 Usage by Envelope Glycoproteins from Human Immunodeficiency Virus Type 1 Primary Isolates

C. Broder, E. Berger, G. Alkhatib, 1998, Journal of Virology.

The block to HIV-1 envelope glycoprotein-mediated membrane fusion in animal cells expressing human CD4 can be overcome by a human cell component(s).

C. Broder, D. Dimitrov, R. Blumenthal, 1993, Virology.

The HIV Coreceptor Repertoire

J. Farber, E. Berger, 1999 .

Maturation of Eosinophilic HL-60 Cells Differentially Regulated by IL-5 During CC Chemokine Receptors 1 and 3 Are

C. Combadière, P. Murphy, E. Berger, 1998 .

An immunotoxin targeting the gH glycoprotein of KSHV for selective killing of cells in the lytic phase of infection.

Yíngyún Caì, E. Berger, 2011, Antiviral research.

Anti‐HIV Effects of CD4‐Pseudomonas Exotoxin on Human Lymphocyte and Monocyte/Macrophage Cell Lines

B. Moss, P. Ashorn, E. Berger, 1990, Annals of the New York Academy of Sciences.

HIV-1-Specific Chimeric Antigen Receptor T Cells Fail To Recognize and Eliminate the Follicular Dendritic Cell HIV Reservoir In Vitro

E. Connick, G. F. Burton, E. Berger, 2020, Journal of Virology.

VirusEffective at Suppressing HIV and Simian Immunodeficiency Domains Are Phenotypically and Functionally Distinct and HIV-Specific CAR T Cells with CD28 or 4-1BB Signaling

M. Pampusch, A. Rendahl, P. Skinner, 2022 .

Assay and characterization of carbohydrate binding by the lectin discoidin I immobilized on nitrocellulose.

E. Berger, R. Kohnken, 1987, Biochemistry.

Human immunodeficiency virus type 1 envelope glycoprotein molecules containing membrane fusion-impairing mutations in the V3 region efficiently undergo soluble CD4-stimulated gp120 release.

P. Earl, J. Sisler, E. Berger, 1992, Journal of Virology.

Binding region for human immunodeficiency virus (HIV) and epitopes for HIV-blocking monoclonal antibodies of the CD4 molecule defined by site-directed mutagenesis.

B. Moss, T. Fuerst, T. Mizukami, 1988, Proceedings of the National Academy of Sciences of the United States of America.

Affinity labeling of the carbohydrate binding site of the lectin discoidin I using a photoactivatable radioiodinated monosaccharide.

E. Berger, R. Kohnken, 1987, Biochemistry.

Expression of foreign genes in cultured human primary macrophages using recombinant vaccinia virus vectors.

C. Broder, E. Berger, P. Kennedy, 1994, Gene.

Vaccinia virus vectors for study of membrane fusion mediated by human immunodeficiency virus envelope glycoprotein and CD4.

B. Moss, P. Ashorn, E. Berger, 1993, Methods in enzymology.

Therapeutic strategies employing CD4, the HIV receptor.

B. Moss, P. Ashorn, E. Berger, 1992, Advances in experimental medicine and biology.

CD4-Pseudomonas Exotoxin: A Strategy for AIDS Therapy Based on Selective Killing of HIV-Infected Cells

B. Moss, P. Ashorn, E. Berger, 1991 .

Blocking HIV-1 gp120 at the Phe43 cavity: if the extension fits….

E. Berger, B. Dey, 2013, Structure.

CD46 on glial cells can function as a receptor for viral glycoprotein‐mediated cell–cell fusion

Roland Martin, E. Martinelli, S. Jacobson, 2005, Glia.

Elimination of infectious human immunodeficiency virus from human T-cell cultures by synergistic action of CD4-Pseudomonas exotoxin and reverse transcriptase inhibitors.

J. Weinstein, I. Pastan, B. Moss, 1990, Proceedings of the National Academy of Sciences of the United States of America.

CD4-Pseudomonas exotoxin hybrid protein blocks the spread of human immunodeficiency virus infection in vitro and is active against cells expressing the envelope glycoproteins from diverse primate immunodeficiency retroviruses.

I. Pastan, B. Moss, S. Chakrabarti, 1989, Proceedings of the National Academy of Sciences of the United States of America.

iTIME.219: An Immortalized KSHV Infected Endothelial Cell Line Inducible by a KSHV-Specific Stimulus to Transition From Latency to Lytic Replication and Infectious Virus Release

Stephen J Dollery, E. Berger, E. Brenner, 2021, Frontiers in Cellular and Infection Microbiology.

Stimulation of glycoprotein gp120 dissociation from the envelope glycoprotein complex of human immunodeficiency virus type 1 by soluble CD4 and CD4 peptide derivatives: implications for the role of the complementarity-determining region 3-like region in membrane fusion.

J. Lifson, L. Eiden, E. Berger, 1991, Proceedings of the National Academy of Sciences of the United States of America.

Immunotoxin Complementation of HAART to Deplete Persisting HIV-Infected Cell Reservoirs

I. Pastan, E. Berger, 2010, PLoS pathogens.

Interaction of Glycoprotein H of Human Herpesvirus 6 with the Cellular Receptor CD46*

J. Atkinson, P. Lusso, M. Liszewski, 2003, Journal of Biological Chemistry.

Human Herpesvirus 6 and Measles Virus Employ Distinct CD46 Domains for Receptor Function*

P. Lusso, E. Berger, Heather L. Greenstone, 2002, The Journal of Biological Chemistry.

Broad target cell selectivity of Kaposi's sarcoma-associated herpesvirus glycoprotein-mediated cell fusion and virion entry.

E. Berger, J. Kaleeba, 2006, Virology.

Calcium ions are required for cell fusion mediated by the CD4-human immunodeficiency virus type 1 envelope glycoprotein interaction

C. Broder, D. Dimitrov, R. Blumenthal, 1993, Journal of virology.

Calcium IonsAreRequired forCellFusion Mediated bythe CD4-HumanImmunodeficiency VirusType1Envelope Glycoprotein Interaction

E. Berger, 1993 .

Glycoprotein K8.1A of Kaposi's Sarcoma-Associated Herpesvirus Is a Critical B Cell Tropism Determinant Independent of Its Heparan Sulfate Binding Activity

Stephen J Dollery, E. Berger, Deboeeta Chatterjee, 2018, Journal of Virology.

CC CKR5: A RANTES, MIP-1α, MIP-1ॆ Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1

C. Broder, C. Combadière, P. Murphy, 1996, Science.

Identification of CX3CR1. A chemotactic receptor for the human CX3C chemokine fractalkine and a fusion coreceptor for HIV-1.

C. Combadière, P. Murphy, K. Salzwedel, 1998, The Journal of biological chemistry.

STRL33, A Novel Chemokine Receptor–like Protein, Functions as a Fusion Cofactor for Both Macrophage-tropic and T Cell Line–tropic HIV-1

K. Peden, J. Farber, E. Berger, 1997, The Journal of experimental medicine.

Inherited Resistance to HIV-1 Conferred by an Inactivating Mutation in CC Chemokine Receptor 5: Studies in Populations with Contrasting Clinical Phenotypes, Defined Racial Background, and Quantified Risk

D. Weissman, R. Detels, A. Fauci, 1997, Molecular medicine.

HIV-1 coreceptor activity of CCR5 and its inhibition by chemokines: independence from G protein signaling and importance of coreceptor downmodulation.

M. Locati, P. Murphy, E. Berger, 1997, Virology.

Different mechanisms of energy coupling for the active transport of proline and glutamine in Escherichia coli.

E. Berger, 1973, Proceedings of the National Academy of Sciences of the United States of America.

CAR/CXCR5-T cell immunotherapy is safe and potentially efficacious in promoting sustained remission of SIV infection

E. Rakasz, M. Pampusch, E. Connick, 2021, bioRxiv.

Development of an anti-CAR antibody response in SIV-infected rhesus macaques treated with CD4-MBL CAR/CXCR5 T cells

E. Rakasz, M. Pampusch, A. Rendahl, 2022, Frontiers in Immunology.

Simian Immunodeficiency Virus (SIV)-Specific Chimeric Antigen Receptor-T Cells Engineered to Target B Cell Follicles and Suppress SIV Replication

E. Rakasz, M. Pampusch, E. Connick, 2018, Front. Immunol..

CD46 Is a Cellular Receptor for Human Herpesvirus 6

M. Malnati, P. Lusso, E. Berger, 1999, Cell.

Functional and structural interactions between measles virus hemagglutinin and CD46

C. Broder, B. Moss, S. Rozenblatt, 1995, Journal of virology.

Evaluation of chimeric antigen receptor T cell therapy in non-human primates infected with SHIV or SIV

M. Roederer, G. Pavlakis, E. Berger, 2021, PloS one.

Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity

S. Rosenberg, R. Morgan, Zhili Zheng, 2015, Journal of Virology.

Targeted cytotoxic therapy: adapting a rapidly progressing anticancer paradigm for depletion of persistent HIV-infected cell reservoirs

E. Berger, 2011, Current opinion in HIV and AIDS.

Molecular characterization, reactivation, and depletion of latent HIV.

D. Hamer, J. Zack, D. Brooks, 2003, Immunity.

Cyanovirin-N Binds to gp120 To Interfere with CD4-Dependent Human Immunodeficiency Virus Type 1 Virion Binding, Fusion, and Infectivity but Does Not Affect the CD4 Binding Site on gp120 or Soluble CD4-Induced Conformational Changes in gp120

Q. Sattentau, M. Boyd, J. Lifson, 1999, Journal of Virology.

HIV entry and tropism: the chemokine receptor connection.

E. Berger, 1997, AIDS.

Biosynthesis of beta nerve growth factor in mouse submaxillary glands.

E. Shooter, E. Berger, 1978, Journal of Biological Chemistry.

Fusogenic selectivity of the envelope glycoprotein is a major determinant of human immunodeficiency virus type 1 tropism for CD4+ T-cell lines vs. primary macrophages.

C. Broder, E. Berger, Christopher C. Broder, 1995, Proceedings of the National Academy of Sciences of the United States of America.

CD26 antigen and HIV fusion?

C. Broder, W. Bachovchin, E. Berger, 1994, Science.

CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1.

C. Broder, C. Combadière, P. Murphy, 1996, Science.

Targeted Cytotoxic Therapy Kills Persisting HIV Infected Cells During ART

M. Hudgens, I. Pastan, A. Haase, 2014, PLoS pathogens.

Multiple Antiviral Activities of Cyanovirin-N: Blocking of Human Immunodeficiency Virus Type 1 gp120 Interaction with CD4 and Coreceptor and Inhibition of Diverse Enveloped Viruses

M. Boyd, D. L. Lerner, P. Lusso, 2000, Journal of Virology.

HIV entry and tropism. When one receptor is not enough.

E. Berger, 1998, Advances in experimental medicine and biology.

Anti-HIV activity of CD4-Pseudomonas exotoxin on infected primary human lymphocytes and monocyte/macrophages.

B. Moss, M. Martin, G. Englund, 1991, The Journal of infectious diseases.

[38] The purification and properties of the glutamine-binding protein and the cystine-binding protein from Escherichia coli

L. Heppel, J. Weiner, E. Berger, 1974 .

STUDIES ON BINDING PROTEINS, PERIPLASMIC ENZYMES AND ACTIVE TRANSPORT IN ESCHERICHIA COLI

I. Friedberg, L. Heppel, J. Weiner, 1972 .

Different mechanisms of energy coupling for the shock-sensitive and shock-resistant amino acid permeases of Escherichia coli.

L. Heppel, E. Berger, 1974, The Journal of biological chemistry.

Discoidins I and II: common and unique regions on two lectins implicated in cell--cell cohesion in Dictyostelium discoideum.

D. Armant, E. Berger, 1982, Proceedings of the National Academy of Sciences of the United States of America.

A binding protein involved in the transport of cystine and diaminopimelic acid in Escherichia coli.

L. Heppel, E. Berger, 1972, The Journal of biological chemistry.

Neutralization of Human Immunodeficiency Virus Type 1 by sCD4-17b, a Single-Chain Chimeric Protein, Based on Sequential Interaction of gp120 with CD4 and Coreceptor

E. Berger, B. Dey, Christie S. Del Castillo, 2003, Journal of Virology.

Sequential CD4-Coreceptor Interactions in Human Immunodeficiency Virus Type 1 Env Function: Soluble CD4 Activates Env for Coreceptor-Dependent Fusion and Reveals Blocking Activities of Antibodies against Cryptic Conserved Epitopes on gp120

K. Salzwedel, E. Berger, B. Dey, 2000, Journal of Virology.

An immunotoxin targeting Ebola virus glycoprotein inhibits Ebola virus production from infected cells

J. Kuhn, S. Radoshitzky, Yíngyún Caì, 2021, PloS one.

A human immunodeficiency virus-transgenic mouse model for assessing interventions that block microbial-induced proviral expression.

A. Sher, M. Schito, E. Berger, 2001, The Journal of infectious diseases.

Anti‐HIV‐1 immunotoxin 3B3(Fv)‐PE38: enhanced potency against clinical isolates in human PBMCs and macrophages, and negligible hepatotoxicity in macaques

I. Pastan, M. Gallo, Qing-cheng Wang, 2006, Journal of leukocyte biology.

Increased Affinity and Stability of an Anti-HIV-1 Envelope Immunotoxin by Structure-based Mutagenesis*

Ira Pastan, I. Pastan, D. Hamer, 2002, The Journal of Biological Chemistry.

Specific Killing of HIV-infected Lymphocytes by a Recombinant Immunotoxin Directed against the HIV-1 Envelope Glycoprotein

C. Barbas, I. Pastan, E. Berger, 1998, Molecular medicine.

Chimeric toxins targeted to the human immunodeficiency virus type 1 envelope glycoprotein augment the in vivo activity of combination antiretroviral therapy in thy/liv-SCID-Hu mice.

I. Pastan, E. Berger, H. Goldstein, 2000, The Journal of infectious diseases.

Distinct developmental regulation and properties of the responsiveness of different genes to cyclic AMP in Dictyostelium discoideum.

E. Berger, D. Bozzone, 1987, Differentiation; research in biological diversity.

Interdomain Stabilization Impairs CD4 Binding and Improves Immunogenicity of the HIV-1 Envelope Trimer.

E. Go, H. Desaire, J. Mascola, 2018, Cell host & microbe.

Intraprotomer masking of third variable loop (V3) epitopes by the first and second variable loops (V1V2) within the native HIV-1 envelope glycoprotein trimer

P. Lusso, E. Berger, R. Cimbro, 2011, Proceedings of the National Academy of Sciences.

Nerve growth factor: studies on the localization, regulation and mechanism of its biosynthesis.

E. Shooter, E. Berger, Eric M. Shooter, 1978, The ... Symposium. Society for Developmental Biology. Symposium.

Assembly and release of infectious hepatitis C virus involving unusual organization of the secretory pathway.

E. Berger, B. Saunier, M. Triyatni, 2016, World journal of hepatology.

Cooperative subunit interactions within the oligomeric envelope glycoprotein of HIV-1: functional complementation of specific defects in gp120 and gp41.

K. Salzwedel, E. Berger, 2000, Proceedings of the National Academy of Sciences of the United States of America.

Cryptic Nature of a Conserved, CD4-Inducible V3 Loop Neutralization Epitope in the Native Envelope Glycoprotein Oligomer of CCR5-Restricted, but Not CXCR4-Using, Primary Human Immunodeficiency Virus Type 1 Strains

P. Earl, R. Longhi, C. Ripamonti, 2005, Journal of Virology.

Introduction: HIV co-receptors solve old questions and raise many new ones.

E. Berger, Edward A. Berger, 1998, Seminars in immunology.

Specific cell-cell contact serves as the developmental signal to deactivate discoidin I gene expression in Dictyostelium discoideum.

J. Clark, E. Berger, 1983, Proceedings of the National Academy of Sciences of the United States of America.

Relationships between cell-cell interactions, cAMP, and gene expression in a developmental mutant ofDictyostelium discoideum

E. Berger, D. Bozzone, R. Kohnken, 1987, Neurochemical Research.

Finding Fusin/CXCR4, the First “2nd Receptor” for HIV Entry

E. Berger, 2015, Front. Immunol..

STUDIES ON THE BIOSYNTHESIS AND STRUCTURE OF NERVE GROWTH FACTOR FROM THE MOUSE SUBMAXILLARY GLAND

E. Shooter, E. Berger, D. Ishii, 1976 .

Natural and engineered antibodies against HIV

E. Berger, 2006, Retrovirology.

Complementation of diverse HIV-1 Env defects through cooperative subunit interactions: a general property of the functional trimer

K. Salzwedel, E. Berger, 2009, Retrovirology.

CD4 molecules with a diversity of mutations encompassing the CDR3 region efficiently support human immunodeficiency virus type 1 envelope glycoprotein-mediated cell fusion

C. Broder, E. Berger, E A Berger, 1993, Journal of virology.

STRL33, A Novel Chemokine Receptor–like Protein, Functions as a Fusion Cofactor for Both Macrophage-tropic and T Cell Line–tropic HIV-1

K. Peden, J. Farber, E. Berger, 1997, The Journal of experimental medicine.

AIDS Vaccine Development

G Gonsalves, M Agosto, N. Haigwood, 1998, Science.

Towards an HIV cure based on targeted killing of infected cells: different approaches against acute versus chronic infection

E. Berger, B. Dey, 2015, Current opinion in HIV and AIDS.

Immunochemical Analysis of Discoidins I and II at the Cell Surface in Wild Type and Aggregation‐Defective Mutants of Dictyostelium discoideum

D. Armant, E. Berger, 1982, Journal of cellular biochemistry.

Different mechanisms of energy coupling for the active transport of proline and glutamine in Escherichia coli.

E. Berger, 1973, Proceedings of the National Academy of Sciences of the United States of America.

STUDIES ON THE BIOSYNTHESIS AND STRUCTURE OF NERVE GROWTH FACTOR FROM THE MOUSE SUBMAXILLARY GLAND

E. Shooter, E. Berger, D. Ishii, 1976 .